Diagnosis and treatment of melanoma bone metastasis: A multidisciplinary approach

Caldaria, Antonio; Giuffrida, Roberta; Meo, Nicola di; Massari, Leo; Dianzani, Caterina; Cannavò, Serafinella Patrizia; Degrassi, Ferruccio; Casablanca, Edoardo; Zalaudek, Iris; Conforti, Claudio

doi:10.1111/dth.14193

Cited by 10 publications

(10 citation statements)

References 50 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nodular melanoma is more common in males than females. It is often ulcerated with the tendency of more vertical growth than traditional radial growth [ 2 ]. Lentigo maligna melanoma correlates with long-term sun exposure and increasing age that may develop for decades before invading the papillary dermis.…”

Section: Discussionmentioning

confidence: 99%

“…Bone is the fourth frequent distant metastatic organ. Melanoma bone metastasis usually occur in patients who already have widespread metastases in other organs [ 2 ]. Herein, we present a rare case of ALM lesion which was originally found in the base of right fifth toe plantar with multiple bone metastases but without any other organs involving.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acral lentiginous melanoma with multiple bone metastasis: case report

Chen¹,

Manvar²,

Chaudhry³

et al. 2023

Pan Afr Med J

View full text Add to dashboard Cite

Acral lentiginous melanoma (ALM) is a type of melanoma that is traditionally seen on the soles of the feet, palms of the hand, and under the fingernails or toenails. It is the least frequently diagnosed melanoma among the four histologic subtypes of cutaneous melanoma, accounting for less than 5% of all cases. ALM is frequently diagnosed at late stages and has higher incidences in non-white populations in relation to the other forms of cutaneous malignant melanoma. The most common sites of metastases in melanoma are the skin and subcutaneous tissue followed by lung, liver, brain, and bone. Bone metastases from malignant melanoma usually occur in patients who already have widespread metastases. We present this paper as a unique case study of ALM lesion in an 84-year-old African American male presenting originally in the base of right fifth toe plantar aspect then found multiple bone metastases without any other organ involved.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Acral lentiginous melanoma with multiple bone metastasis: case report

Chen¹,

Manvar²,

Chaudhry³

et al. 2023

Pan Afr Med J

View full text Add to dashboard Cite

show abstract

“…The antitumor activity of D16F7 mAb includes a marked inhibitory effect on the ability of melanoma to infiltrate bone marrow, reducing the levels of PlGF that can attract more VEGFR-1-expressing tumor cells. This finding is of particular relevance, given that bone is the fourth most common site of melanoma metastasis and that patients with multiple skeletal events have a dismal prognosis [ 40 , 41 ]. The results of in vitro studies indicated that D16F7 mAb was also able to induce a reduction in PlGF release in melanoma culture supernatants, likely contributing to a restrained tumor invasiveness.…”

Section: Discussionmentioning

confidence: 99%

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor

Atzori

Ceci

Ruffini

et al. 2022

Cancers

View full text Add to dashboard Cite

Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family involved in tumor-associated angiogenesis and melanoma invasion of the extra-cellular matrix (ECM) through activation of membrane VEGF receptor 1 (VEGFR-1). A soluble VEGFR-1 (sVEGFR-1) form is released in the ECM, where it sequesters proangiogenic factors and stimulates endothelial or tumor cell adhesion and chemotaxis through interaction with α5β1 integrin. The anti-VEGFR-1 monoclonal antibody (D16F7 mAb) inhibits VEGF-A or PlGF-mediated signal transduction without affecting ligand interaction, thus preserving sVEGFR-1 decoy function. The aim of this study was to investigate whether D16F7 mAb hampers melanoma spread by in vitro analysis of cell adhesion to sVEGFR-1, ECM invasion, transmigration through an endothelial cell monolayer and in vivo evaluation of tumor infiltrative potential in a syngeneic murine model. Results indicate that D16F7 mAb significantly inhibits melanoma adhesion to sVEGFR-1 and ECM invasion, as well as transmigration in response to PlGF. Moreover, treatment of melanoma-bearing mice with the anti-VEGFR-1 mAb not only inhibits tumor growth but also induces a significant reduction in bone infiltration associated with a decrease in PlGF-positive melanoma cells. Furthermore, D16F7 mAb reduces PlGF production by melanoma cells. Therefore, blockade of PLGF/VEGFR-1 signaling represents a suitable strategy to counteract the metastatic potential of melanoma.

show abstract

“…Overcoming these challenges requires a multidisciplinary approach combining innovative therapeutic strategies, imaging and diagnostic techniques advancements, and a comprehensive understanding of the BME ( 196 ). By addressing these challenges head-on, researchers and clinicians aim to improve outcomes for patients with bone-metastatic cancers, enhance the quality of life, and develop more effective treatment options tailored to the unique characteristics of this disease.…”

Section: Challenges In Bone-metastatic Cancer Treatmentmentioning

confidence: 99%

Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers

Lan,

Wu,

Jin

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

Evidence demonstrated that bones, liver, and lungs are the most common metastasis sites in some human malignancies, especially in prostate and breast cancers. Bone is the third most frequent target for spreading tumor cells among these organs and tissues. Patients with bone-metastatic cancers face a grim prognosis characterized by short median survival time. Current treatments have proven insufficient, as they can only inhibit metastasis or tumor progression within the bone tissues rather than providing a curative solution. Gaining a more profound comprehension of the interplay between tumor cells and the bone microenvironment (BME) is of utmost importance in tackling this issue. This knowledge will pave the way for developing innovative diagnostic and therapeutic approaches. This review summarizes the mechanisms underlying bone metastasis and discusses the clinical aspects of this pathologic condition. Additionally, it highlights emerging therapeutic interventions aimed at enhancing the quality of life for patients affected by bone-metastatic cancers. By synthesizing current research, this review seeks to shed light on the complexities of bone metastasis and offer insights for future advancements in patient care.

show abstract

Diagnosis and treatment of melanoma bone metastasis: A multidisciplinary approach

Cited by 10 publications

References 50 publications

Acral lentiginous melanoma with multiple bone metastasis: case report

Acral lentiginous melanoma with multiple bone metastasis: case report

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor

Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers

Contact Info

Product

Resources

About